Overview

Please note that this product (marketed as Sarclisa) was withdrawn from the Union Register of orphan medicinal products in April 2020 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

This medicine is now known as isatuximab.

On 29 April 2014, orphan designation (EU/3/14/1268) was granted by the European Commission to Sanofi-Aventis Groupe, France, for humanised monoclonal antibody against CD38 for the treatment of plasma cell myeloma.

Plasma cell myeloma (also called multiple myeloma) is a cancer of a type of white blood cell called plasma cells. Plasma cells originate from the bone marrow, the spongy tissue inside the large bones in the body. In plasma cell myeloma the division of plasma cells becomes out of control, resulting in abnormal, immature plasma cells multiplying and filling up the bone marrow. This interferes with the production of normal white blood cells, red blood cells and platelets (components that help the blood to clot), leading to complications such as anaemia (low red blood cell counts), bone pain and fractures, raised blood calcium levels and kidney disease.

Plasma cell myeloma is a debilitating and life-threatening disease particularly because it disrupts the normal functioning of the bone marrow, damages the bones and causes kidney failure.

At the time of designation, plasma cell myeloma affected approximately 1.8 in 10,000 people in the European Union (EU). This was equivalent to a total of around 92,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This isbased on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).


*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. At the time of designation, this represented a population of 512,900,000 (Eurostat 2014).

At the time of designation, several medicines were already authorised for plasma cell myeloma in the EU. The main treatment for plasma cell myeloma was chemotherapy (medicines to treat cancer) usually combined with steroids to reduce the activity of the immune system, the body's natural defences. Where chemotherapy did not work, some patients received an allogeneic stem-cell transplant (a complex procedure where the patient receives stem cells from a matched donor to help restore the bone marrow). Radiotherapy (using radiation to kill cancer cells) was used to treat pain due to bone damage and prevent further damage. Interferon alfa was sometimes used in combination with chemotherapy.

The sponsor has provided sufficient information to show that the medicine might be of significant benefit to patients with plasma cell myeloma because it works in a different way to existing treatments and early studies showed some improvements in patients whose cancer had come back or did not respond to standard treatment. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

This medicine is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific target. The target for this medicine is a protein called CD38, which is present on the surface of many white blood cells but occurs in higher amounts in some blood cancers, including plasma cell myeloma. By attaching to CD38 on the cancerous plasma cells, the medicine is expected to activate certain components of the immune system so that they kill the cancerous plasma cells. It is also expected to interfere with cell survival thus causing the death of the cancer cells. This is expected to slow down the development of plasma cell myeloma.

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials with the medicine in patients with plasma cell myeloma were ongoing.

At the time of submission, the medicine was not authorised anywhere in the EU for plasma cell myeloma or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 12 March 2014 recommending the granting of this designation.

  • the seriousness of the condition;
  • the existence of alternative methods of diagnosis, prevention or treatment;
  • either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

EU/3/14/1268: Public summary of opinion on orphan designation: Humanised monoclonal antibody against CD38 for the treatment of plasma cell myeloma

Key facts

Active substance
Humanised monoclonal antibody against CD38 for the treatment of plasma cell myeloma (isatuximab)
Intended use
Treatment of plasma cell myeloma
Orphan designation status
Withdrawn
EU designation number
EU/3/14/1268
Date of designation
Sponsor

Sanofi-Aventis Groupe
54 rue de la Boétie
75008 Paris
France
Tel. +33 153 774 000
Fax +33 153 774 133
E-mail: www.sanofi-aventis.com/contact/contact.asp

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Sarclisa at the time of marketing authorisation.

The sponsor formally requested the withdrawal of the orphan designation prior to the Committee’s final opinion. More information is available in the Sarclisa : Orphan designation withdrawal assessment report (initial authorisation).

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

EMA list of opinions on orphan medicinal product designation

EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

How useful do you find this page?